The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
The cognitive sequelae of standard‐dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial
Open accessAbstract
BACKGROUND: Retrospective trials have reported that chemotherapy‐induced cognitive dysfunction was experienced by a subset of patients with breast carcinoma. However, recent evidence indicated that a subset also exhibited impaired cognitive function at baseline, before the start of chemotherapy. A prospective, longitudinal trial that incorporates baseline neuropsychologic evaluations is necessary to determine to what extent cognitive dysfunction is attributable to chemotherapy in this population. METHODS: Eighteen women with breast carcinoma underwent a comprehensive neuropsychologic evaluation before treatment and at short‐term and long‐term intervals after chemotherapy. The incidence, nature, severity, and chronicity of cognitive dysfunction developing in patients with breast carcinoma treated with a standard dose of adjuvant chemotherapy were assessed. RESULTS: Before the start of systemic therapy, 33% of women in the current cohort exhibited cognitive impairment. At the short‐term postchemotherapy time point, 61% of the cohort exhibited a decline relative to baseline in 1 or more domains of cognitive functioning and reported greater difficulty in maintaining their ability to work. The most common domains of cognitive dysfunction were related to attention, learning, and processing speed. At the long‐term postchemotherapy time point, approximately 50% of patients who experienced declines in cognitive function demonstrated improvement, whereas 50% remained stable. Self‐reported ability to perform work‐related activities also improved over this interval. Neither impairment at baseline nor subsequent treatment‐related cognitive decline exhibited any statistically significant correlation with affective well‐being or with demographic or clinical characteristics. CONCLUSIONS: The current study is the first longitudinal trial to report evidence of an association between cognitive dysfunction and chemotherapy in a subgroup of women with nonmetastatic breast carcinoma. The importance of using prospective research designs, appropriate cognitive measures, and statistical methods to evaluate subgroup effects was discussed. Identification of mechanisms associated with cognitive dysfunction and of risk factors contributing to subgroup vulnerability is necessary. Cancer 2004. © 2004 by the American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jacobson, N. S., & Truax, P. (1991) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.59.1.12 · Cited by 7,770
Clinical neuropsychology: Current status and applications
(1975) · Behavior Therapy · doi:10.1016/s0005-7894(75)80088-8 · Cited by 1,552
Multilingual Aphasia Examination
Patterson, J. P. (2018) · Encyclopedia of Clinical Neuropsychology · doi:10.1007/978-3-319-57111-9_900 · Cited by 1,096
van Dam, F. S. A. M., Boogerd, W., Schagen, S. B., Muller, M. J., Droogleever Fortuyn, M. E., Wall, E. V. D., & Rodenhuis, S. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.3.210 · Cited by 763
Ahles, T. A., Saykin, A. J., Furstenberg, C. T., Cole, B., Mott, L. A., Skalla, K., Whedon, M. B., Bivens, S., Mitchell, T., Greenberg, E. R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.485 · Cited by 736
Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma
Schagen, S. B., van Dam, F. S. A. M., Muller, M. J., Boogerd, W., Lindeboom, J., & Bruning, P. F. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990201)85:3<640::aid-cncr14>3.0.co;2-g · Cited by 620
Cognitive Function in Breast Cancer Patients Receiving Adjuvant Chemotherapy
Brezden, C. B., Phillips, K.-A., Abdolell, M., Bunston, T., & Tannock, I. F. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.14.2695 · Cited by 557
Kløve, H. (1963) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)33515-5 · Cited by 407
Tchen, N., Juffs, H. G., Downie, F. P., Yi, Q.-L., Hu, H., Chemerynsky, I., Clemons, M., Crump, M., Goss, P. E., Warr, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.119 · Cited by 380
The MMPI-2/MMPI: An Interpretive Manual
Greene, R. L. (1980) · Medical Entomology and Zoology · Cited by 345
Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer
Wieneke, M. H., & Dienst, E. R. (1995) · Psycho-Oncology · doi:10.1002/pon.2960040108 · Cited by 317
Psychological interventions for cancer patients to enhance the quality of life.
Andersen, B. L. (1992) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.60.4.552 · Cited by 317
ANDERSON-HANLEY, C., SHERMAN, M. L., RIGGS, R., AGOCHA, V. B., & COMPAS, B. E. (2003) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617703970019 · Cited by 302
Selective reminding test: An examination of the equivalence of four forms
Hannay, H. J., & Levin, H. S. (1985) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/01688638508401258 · Cited by 248
Ingraham, L. J., & Aiken, C. B. (1996) · Neuropsychology · doi:10.1037//0894-4105.10.1.120 · Cited by 234
Fletcher, J. M. (1985) · Journal of Experimental Child Psychology · doi:10.1016/0022-0965(85)90088-8 · Cited by 191
Neurotoxicity secondary to antineoplastic drugs
Tuxen, M. K., & Hansen, S. W. (1994) · Cancer Treatment Reviews · doi:10.1016/0305-7372(94)90027-2 · Cited by 167
Takimoto, C. H. M., Lu, Z. H., Zhang, R., Liang, M. D., Larson, L., Cantilena, L. R., Grem, J. L., Allegra, C. J., Diasio, R. B., & Chu, E. (1996) · PubMed · Cited by 164
Fluorouracil-Induced Neurotoxicity
Pirzada, N. A., Ali, I., & Dafer, R. M. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.18425 · Cited by 142
Minnesota Multiphasic Personality Inventory
Temple, R. (2017) · Springer eBooks · doi:10.1007/978-3-319-56782-2_1999-2 · Cited by 129
5-Fluorouracil-induced leukoencephalopathy in patients with breast cancer
Choi, S. M., Lee, S., Yang, Y. S., Kim, B. C., Kim, M. K., & Cho, K. H. (2001) · Journal of Korean Medical Science · doi:10.3346/jkms.2001.16.3.328 · Cited by 76
Brief report development of a booklet form of the category test: Normative and validity data
DeFilippis, N. A., McCampbell, E., & Rogers, P. (1979) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/01688637908401108 · Cited by 54
Cited by
Cancer treatment and survivorship statistics, 2012
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,928
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Wefel, J. S., Vardy, J., Ahles, T., & Schagen, S. B. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70294-1 · Cited by 998
Self-citationBrain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium
Bondy, M. L., Scheurer, M. E., Malmer, B., Barnholtz-Sloan, J. S., Davis, F. G., Il'yasova, D., Kruchko, C., McCarthy, B. J., Rajaraman, P., Schwartzbaum, J. A., et al. (2008) · Cancer · doi:10.1002/cncr.23741 · Cited by 932
Candidate mechanisms for chemotherapy-induced cognitive changes
Ahles, T. A., & Saykin, A. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2073 · Cited by 916
Metadata
- Authors
- Wefel, J. S., Lenzi, R., Theriault, R. L., Davis, R. N., & Meyers, C. A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004-04-28
- Volume
- 100
- Issue
- 11
- Pages
- 2292-2299
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2009666348
- Cited by
- 679
- References
- 22
- FWCI
- 21.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.